New Delhi: Drug firm Wockhardt on Monday said the US health regulator has excluded Ceftriazone Sodium from import alert issued earlier against its active pharmaceutical ingredient manufacturing facility at Ankleshwar.

The United States Food and Drug Administration (USFDA) on September 30, 2016 has posted on its website an update on the Import Alert 66-40 "regarding company's API Unit at Ankleshwar" and excluded Ceftriazone Sodium from it, Wockhardt said in a filing to BSE.

"This will enable the company to manufacture and sell Ceftriazone API and formulation to US market," it added.

Shares of Wockhardt closed at Rs 894.45 per scrip on BSE, up 1.86 per cent from its previous close.

Subscribe ETHealthworld Newsletter

Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

With this acquisition, Nephroplus will further strengthen its servicing capacity as the dominant dialysis centre network and will have a presence in 18 states of India with 176 centers across 97 cities.